MATERIALS AND METHODS

The study participants
The Auckland Prostate Study is a population based case-control study which was carried out in the greater metropolitan area of Auckland, New Zealand. The study population included all men aged 40-80 years normally resident in the Auckland area during the 13-month study recruitment period from January 1996. Almost all men with newly diagnosed prostate cancer in this Auckland population age group attend specialist urologists, either in one public hospital-based clinic, or one of three private clinics involving seven urologists. In this study, all public hospital urology clinic attendees and patients attending five of seven private clinic urologists were eligible for participation. In order to improve response rates and reduce dietary assessment biases arising from knowledge of a recent cancer diagnosis, the majority of prostate cancer cases were recruited prospectively from a larger group of urology clinic attendees prior to the completion of clinic investigations for prostate cancer. The remainder of prostate cancer cases in the study population were identified retrospectively from histology reports, but within 3 weeks of the cancer diagnosis. All prostate cancer cases were confirmed by reference to histology reports. The study identified a sub-group of 'advanced' cancer cases who were men with clinically significant disease. The definition of 'advanced' cancers was defined prior to study analyses and was based upon tumour stage and grade. It comprised cases with documented pathological or radiological evidence of tumour invasion beyond the prostate capsule, or a tumour with a combined Gleason score of seven or more.
Study controls comprised men aged 40-80 years, with no history of prostate cancer, randomly selected from the general electoral rolls (these provide 95% coverage of adult European men Prostate cancer risk and consumption of fish oils: a dietary biomarker-based caseÐcontrol study in the Auckland region). Control participants were group-matched to cases during the study recruitment period using 10-year age groups and an approximate case-control ratio of 1:1.5. Approval to carry out the study was obtained from the Northern Regional Health Authority Ethics Committee and written consent was obtained from all participants.
Collection of questionnaire data
Identical procedures were used for exposure data collection from cases and controls. Study participants completed self-administered questionnaires including a validated 107 food-item food frequency questionnaire (Sharpe et al, 1993 ) and a general questionnaire covering personal, socio-demographic, anthropometric, medical and lifestyle data. Spearman correlation coefficients for estimated intake of total fat and total polyunsaturated fat (food frequency questionnaire vs 7-day food record) were 0.69 and 0.63 respectively (Sharpe et al, 1993) . Research nurses visited all participants at home to obtain blood samples and to check the completeness of responses to the questionnaires which had been posted to participants 1-2 weeks previously. Participants with missing responses were encouraged to fully complete the questionnaires (self-administered) at the time of the visit. Although the nurse-interviewers were not 'blind' to the case-control status of participants, neither they nor the participants were aware of specific hypotheses concerning diet and prostate cancer risk.
Blood sample processing and erythrocyte fatty acid analysis
Ten millilitres of whole blood was collected from participants in EDTA and transported promptly to the laboratory in chilled polystyrene containers. Erythrocytes were separated from plasma and washed three times in HEPES-buffered saline. Centrifugation of samples was carried out at 4°C. Washed erythrocyte samples were transferred to cryovials (Greiner) allowing minimal headspace air in each vial and stored at -82°C for a period of 3-12 months prior to further analysis. Lipids were extracted from packed erythrocytes according to the method of Bligh and Dyer (1959) and fatty acid composition of erythrocyte phosphatidylcholine was determined using gas-liquid chromatography, as described by Holub and Skeaff (1987) . The precision of the fatty acid measurement was determined by repeated analyses (n = 22) of a pooled erythrocyte sample carried out over the analysis period. Coefficients of variation for EPA and DHA were 7.3% and 8.2% respectively. The addition of internal standard to sample and blank extractions permitted sample peak areas to be corrected for background contamination. Quantification of the area under the curves for individual fatty acids allowed calculation of the molar proportion of the total fatty acids. Laboratory staff were kept blind to the case-control status of participants' blood samples.
Statistical analysis
Nutrient consumption was estimated from the food frequency questionnaire data and New Zealand food composition tables (Burlingame et al, 1993) . Categories of exposure for nutrients and the molar percentage of erythrocyte fatty acids were defined by quartiles, based upon the distribution in the control group. Relative risks for total and advanced prostate cancers were calculated for quartile categories, with the reference group comprised of the lowest quartile. Since controls were matched to cases by age group during recruitment, age-adjusted relative risks were calculated for all analyses. Multivariate relative risks were calculated using an unconditional logistic regression model. Age was included as a continuous variable in regression models, but other co-variates were included as categorical terms. Socio-economic status was defined by the participants' usual current or former occupation (if retired), according to the modified Elley-Irving Classification (Johnston, 1983) which has been widely used in New Zealand population research. Energy-adjustment of fatty acid data was carried out by including categorical terms for total energy consumption (derived from the food frequency questionnaire) in the logistic regression model. A test for overall trend across categories used the P-values from a logistic regression model, which included ordinal terms for each quartile of intake as well as confounding co-variates. Total numbers may be incomplete due to missing data for some observations. c Regular use of aspirin or other non-steroidal anti-inflammatory drugs.
RESULTS
Participants in the Auckland Prostate Study included a total of 317 prostate cancer cases (77% response rate) and 480 controls (71% response rate). The results of blood sample analyses were available for 285 cases (90%) and 427 (89%) of study controls. Due to the age-matched recruitment process there was little difference in age distribution of cases and controls, however, cases were of lower socio-economic status and less likely to receive regular treatment with non-steroidal anti-inflammatory drugs (Table 1) . Energy and total fat intake was similar between the two groups, but cases reported a lower mean intake of lycopene and had lower erythrocyte levels of EPA and DHA. Examination of these characteristics amongst participants for whom blood results were available revealed only very minor differences from the total study population.
For the control group the Spearman coefficient (r) for the correlations between erythrocyte phosphatidylcholine EPA measurement and food frequency questionnaire-estimated daily intake of total fish was 0.26; for DHA, Spearman r = 0.32. Similar correlation coefficient values were observed for cases. A significant inverse association was observed between erythrocyte measurements of EPA and DHA and the risk of prostate cancer (Table 2) . This association persisted following adjustment for a number of potential confounding variables included in a multivariate model. Energy-adjusted analyses resulted in negligible differences in relative risk estimates and are not presented. However, estimates of daily EPA and DHA intake derived from the food frequency questionnaire were not significantly associated with prostate cancer risk; the multivariate relative risk for the upper quartile versus the lowest quartile of EPA intake was 0.96 (95% confidence interval (CI) 0.63-1.48); and for DHA intake the relative risk was 1.10 (95% CI 0.71-1.70).
DISCUSSION
This population-based case-control study of prostate cancer has observed a reduction in prostate cancer risk associated with dietary biomarker measurements of EPA and DHA intake, but not with estimated dietary intakes of these fatty acids derived from selfreported food consumption.
A major goal of our study was to incorporate more accurate measurements of dietary exposure to fish oils. The molar proportion of individual erythrocyte fatty acids quantified in our study represents a relative measure of fatty acid exposure integrated over time at the circulation level, closer to the target tissue of concern. This approach reduces some of the uncertainties concerning selfreported diets and nutritional database inadequacies. Several intervention studies of human subjects given controlled diets of EPA and DHA (including those with moderate intake levels) have demonstrated clear associations with the erythrocyte fatty acid composition of these fatty acids (Glatz et al, 1989; Agren and Hanninen, 1991; Brown et al, 1991; Vajreswari and Narayanareddy, 1992) . Although not directly examined in erythrocytes, it has been demonstrated that the consumption of preformed EPA and DHA in the diet leads to a greater increase of these fatty acids in plasma and platelet phospholipids than an equivalent intake of dietary alpha-linolenic acid (Sanders and Roshanai, 1983; Mantzioris et al, 1994) , suggesting that dietary intake, rather than endogenous biosynthesis is the major determinant of circulating levels in humans.
We observed only moderate correlations between erythrocyte levels of EPA and DHA and self-reported fish intake, but similar correlation values existed for prostate cancer cases and controls. These findings are similar to those reported by a previous small case-control study of prostate cancer (Godley et al, 1996a) . They suggest that the food frequency questionnaires used in these studies may not constitute a very sensitive and accurate means of assessing EPA and DHA intake, particularly in study populations with relatively restricted intakes of marine food sources. However, the similar correlations for prostate cancer cases and controls provide indirect evidence that prostate cancer does not seriously disrupt the relationship between dietary fatty acids and their incorporation into erythrocytes, an important theoretical concern with the use of biological measurements of exposure in case-control studies. Although differences in plasma fatty acids observed between colorectal cancer patients and controls have been attributed, at least in part, to metabolic changes associated with malignancy, corresponding differences were not reported for erythrocyte fatty acids in the same study (Baro et al, 1998) .
The initial participant response rates are typical of those achieved by this type of case-control study design; however, incomplete recruitment raises the potential for selection bias in our study. The excluded cases attending two out of seven private urologists were estimated to represent only 9% of the total number of cases, and were expected to be representative of private cases overall. While their exclusion may be expected to contribute to differences in the socio-economic status of cases and controls, all analyses were adjusted for this variable. By comparing the characteristics of participants with available and missing erythrocyte data, we ascertained that the availability of blood sample analyses was unrelated to the exposure or disease status of participants, and unlikely to result in selection bias. Since the majority of cases in our study (60%) provided blood samples and questionnaire data prior to their cancer diagnosis, or shortly after diagnosis in the remainder (retrospectively recruited cases), the potential for bias involving dietary recall or modification may be less than in traditional case-control study designs.
Few previous human prostate cancer studies have investigated associations with marine foods or longer chain n-3 polyunsaturated fatty acids due to dietary assessment limitations. Two case-control studies involving Japanese and British men have suggested that prostate cancer risk may be raised amongst men who reported consuming little seafood in their diet (Mishina et al, 1985; Ewings and Bowie, 1996) , but a cohort study conducted in the USA observed no association with long-chain n-3 fat from fish (Giovannucci et al, 1992) , a result consistent with our own food frequency questionnaire-derived findings. Only three previous studies have incorporated dietary biomarkers. A small urology clinic-based case-control study involving 89 cases and 38 controls has reported a reduced prostate cancer risk associated with the highest quartile of EPA and DHA levels in erythrocytes, but the precision of relative risk estimates was low and there was no clear gradient of risk over increasing levels of exposure (Godley et al, 1996b) . No significant associations with EPA or DHA were noted by two small prospective studies involving 120 cases and 35 cases respectively (Gann et al, 1994; Harvei et al, 1997) , which measured fatty acids in stored serum and plasma samples collected as part of earlier studies (these samples may provide a less valid biomarker measurement of dietary fatty acid intake compared with erythrocyte or adipose tissue samples collected specifically for this purpose).
The underlying cellular and molecular processes by which fish oils may reduce prostate cancer risk have not been established; however, mechanisms involving the inhibition of cancer progression via modulation of arachidonic acid-derived eicosanoid biosynthesis are plausible (Earnest et al, 1992; Lupulescu, 1996) . EPA and DHA have been shown to inhibit the augmented production of PGE 2 by malignant prostate tissue (Chaudry et al, 1994) and cell proliferation rates in human prostate cancer cell lines in vitro (Karmali, 1987; Rose and Connolly, 1991) , although a more recent experimental study demonstrated an inhibitory effect of EPA only at high doses (Pandalai et al, 1996) . Many of these experimental studies have also demonstrated inhibition of prostate cancer cell proliferation with non-steroidal anti-inflammatory drugs (cyclooxygenase inhibitors) and a reduced risk of advanced prostate cancer has been previously reported amongst men in our study who regularly took non-steroidal anti-inflammatory drugs (Norrish et al, 1998) .
In conclusion, our observations of a reduced prostate cancer risk associated with increased levels of long-chain n-3 polyunsaturated fatty acids in erythrocytes are supportive of eicosanoid-based hypotheses for prostate carcinogenesis or progression, and warrant further investigation.
